These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7865644)

  • 21. Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function.
    Cerletti C; Bonati M; del Maschio A; Galletti F; Dejana E; Tognoni G; de Gaetano G
    J Lab Clin Med; 1984 Jun; 103(6):869-77. PubMed ID: 6726057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of platelet function by low-dose plain and micro-encapsulated acetylsalicylic acid.
    Waldemar G; Petersen P; Boysen G; Knudsen JB
    Thromb Res; 1988 Apr; 50(2):265-72. PubMed ID: 3134739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized placebo-controlled study of the effect of low dose aspirin on platelet reactivity and serum thromboxane B2 production in non-pregnant women, in normal pregnancy, and in gestational hypertension.
    Louden KA; Broughton Pipkin F; Symonds EM; Tuohy P; O'Callaghan C; Heptinstall S; Fox S; Mitchell JR
    Br J Obstet Gynaecol; 1992 May; 99(5):371-6. PubMed ID: 1622907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo.
    Kyrle PA; Eichler HG; Jäger U; Lechner K
    Circulation; 1987 May; 75(5):1025-9. PubMed ID: 3552295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function.
    De Caterina R; Giannessi D; Bernini W; Gazzetti P; Michelassi C; L'Abbate A; Donato L; Patrignani P; Filabozzi P; Patrono C
    Eur Heart J; 1985 May; 6(5):409-17. PubMed ID: 3930246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot trial of the effects of low-dose acetylsalicylic acid on platelet thromboxane B2 production.
    Janssen PL; Akkerman JW; Hollman PC; van Staveren WA; Zwaginga JJ; Katan MB
    Eur J Clin Nutr; 1995 May; 49(5):365-70. PubMed ID: 7664723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril.
    Smith SR; Coffman TM; Svetkey LP
    J Am Soc Nephrol; 1993 Nov; 4(5):1133-9. PubMed ID: 8305640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
    Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
    J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease.
    Zoja C; Benigni A; Livio M; Bergamelli A; Orisio S; Abbate M; Bertani T; Remuzzi G
    Am J Pathol; 1989 May; 134(5):1027-38. PubMed ID: 2497648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in the effects of extended-release aspirin and plain-formulated aspirin on prostanoids and nitric oxide in healthy volunteers.
    De La Cruz JP; González-Correa JA; Guerrero A; Márquez E; Martos F; Sánchez De La Cuesta F
    Fundam Clin Pharmacol; 2003 Jun; 17(3):363-72. PubMed ID: 12803576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women.
    Feldman M; Cryer B; Rushin K; Betancourt J
    Clin Appl Thromb Hemost; 2001 Jan; 7(1):53-7. PubMed ID: 11190906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet thromboxane A2/prostaglandin H2 receptors in human volunteers on low doses of aspirin.
    Covatto RH; Niewiarowski S
    Biochem Pharmacol; 1990 Oct; 40(7):1559-61. PubMed ID: 2145839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.
    Cerletti C; Dell'Elba G; Manarini S; Pecce R; Di Castelnuovo A; Scorpiglione N; Feliziani V; de Gaetano G
    Clin Pharmacokinet; 2003; 42(12):1059-70. PubMed ID: 12959636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.
    Chiang N; Bermudez EA; Ridker PM; Hurwitz S; Serhan CN
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15178-83. PubMed ID: 15471991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs.
    Reilly IA; FitzGerald GA
    Blood; 1987 Jan; 69(1):180-6. PubMed ID: 3790723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis.
    Brown N; May JA; Wilcox RG; Allan LM; Wilson AM; Kiff PS; Heptinstall S
    Br J Clin Pharmacol; 1999 Jul; 48(1):57-62. PubMed ID: 10383561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
    Reilly MP; Moran N; Meagher E; Delanty N; Cucchiara AE; Lawson JA; Catella-Lawson F
    J Cardiovasc Pharmacol; 1999 Jan; 33(1):12-8. PubMed ID: 9890391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.
    Bhatt DL; Grosser T; Dong JF; Logan D; Jeske W; Angiolillo DJ; Frelinger AL; Lei L; Liang J; Moore JE; Cryer B; Marathi U
    J Am Coll Cardiol; 2017 Feb; 69(6):603-612. PubMed ID: 28089180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2.
    FitzGerald GA; Lupinetti M; Charman SA; Charman WN
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1043-9. PubMed ID: 1762060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.